Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96)

Koch, P.; Probst, Andreas; Berdel, Wolfgang E.; Willich, Normann; Reinartz, Gabriele; Brockmann, Jens; Liersch, Rüdiger; Valle, Francisco del; Clasen, Hermann; Hirt, Carsten; Breitsprecher, Regine; Schmits, Rudolf; Freund, Mathias; Fietkau, Rainer; Ketterer, Peter; Freitag, E.; Hinkelbein, Margit; Heinecke, Achim; Parwaresch, Reza; Tiemann, Markus

doi:10.1200/jco.2005.04.031

Cited by 227 publications

(151 citation statements)

References 26 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Indeed, PGL of MALT type, when confined to mucosa and sub-mucosa layers responds to HP eradication therapy without any need of chemotherapy, meanwhile DLBCL are usually treated as general disease with chemo-immuno-therapy, even if recent case reports indicated the regression of locally staged DLBCL after HP eradication (Montalban et al, 2001, Tari et al, 2009. Independently from the stage and dissemination, transformation to DLBCL occurs in about 10% of the cases (Zucca et al, 2008 The GIT NHL 02/96 study, confirming the results of the previous study GIT NHL 01/92, revealed that surgery is no longer the better strategy in early-stage low-and high-grade gastric lymphomas (Koch et al, 2005), except when perforation, bleeding or obstruction take place, proving these findings in a cohort of 363 patients. Firstly, the great impact of the stomach-preserving treatment has been suggested by Fischbach in a prospective nonrandomized trial, reporting a survival rate from 89% to 96% at 2 years for low-grade lymphomas and from 83% to 88% for high-grade lymphomas (Fischbach et al, 2000).…”

Section: Prognostic Assessment and Treatment: How Endoscopic Ultrasousupporting

confidence: 57%

Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature

Vetro¹,

Romano²,

Palumbo³

et al. 2011

Ultrasound Imaging - Medical Applications

View full text Add to dashboard Cite

Section: Prognostic Assessment and Treatment: How Endoscopic Ultrasousupporting

confidence: 57%

Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature

Vetro¹,

Romano²,

Palumbo³

et al. 2011

Ultrasound Imaging - Medical Applications

View full text Add to dashboard Cite

“…37,38 Isaacson 39 previously proposed a classification of primary gastrointestinal non-Hodgkin lymphoma that comprised cases of both low-grade and high-grade MALT; however, the current WHO lymphoma classification no longer uses such terminology, and cases of high-grade MALT have been subsumed into the large B-cell lymphoma category (Table 1). 37,40 GASTROINTESTINAL B-CELL LYMPHOMAS, PREDOMINATELY NON-MALT Most primary gastrointestinal lymphomas, both in stomach and intestine and irrespective of their association with MALT, are large B-cell lymphomas, especially those composed of centroblasts, but may also include cases dominated by immunoblasts and, on occasion, plasmablasts. The relationship between the more common large B-cell gastrointestinal lymphomas and the low-grade lymphomas of MALT is unclear.…”

Section: Classification Of Gastrointestinal Lymphomasmentioning

confidence: 99%

Lymphoproliferative Disorders of the Gastrointestinal Tract: A Review and Pragmatic Guide to Diagnosis

Burke

2011

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—The gastrointestinal tract is the most common site of extranodal lymphomas. Although all histologic categories of malignant lymphoma develop in the gastrointestinal tract, large B-cell lymphomas predominate, followed by extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) type; the latter is especially prevalent in stomach. The acceptance of extranodal marginal zone lymphoma of MALT type as a clinicopathologic entity has reduced the number of cases that formerly were interpreted as florid lymphoid hyperplasia (“pseudolymphoma”). Nonetheless, the distinction of lymphoid hyperplasia from a lymphoma of MALT type in small biopsy specimens remains problematic. Objective.—To assess the relevant morphologic, immunologic, molecular, and genetic properties of gastrointestinal lymphomas and to present a feasible tactic for diagnosis, expressly for small biopsy specimens. Data Sources.—Case-derived material and literature review using PubMed (National Library of Medicine). Conclusions.—Most gastrointestinal lymphomas are readily amenable to an unqualified diagnosis, primarily those cases consisting of monomorphic large cells whether of B- or T-cell lineage, including cases associated with enteropathy. Diagnosis for infiltrates dominated by small lymphocytes remains taxing, as the differential diagnosis embraces not only MALT lymphoma and lymphoid hyperplasia but also mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma. Adherence to strict morphologic criteria is the standard for diagnosis, but these criteria should be augmented by immunologic studies together with judicious use of molecular techniques to determine clonality. In establishing a diagnosis of gastric marginal zone lymphoma of MALT type, determination of t(11;18)(q21;q21) status may be required since this translocation has clinical ramifications.

show abstract

“…PGL is a unique disease and has a variety of pathological types, and DLBCL and MALT lymphoma account for the majority of PGLs (97.4%) (4,5). Hp infection is important in the development of PGL.…”

Section: Discussionmentioning

confidence: 99%

“…PGL is the most common extranodal lymphoma, representing 20-40% of all extranodal non-Hodgkin's lymphomas (2,3). Diffuse large B-cell lymphoma (DLBCL) accounts for the majority of PGL (59.5%), followed by the mucosa-associated lymphoid tissue (MALT) type (37.9%) (4,5).…”

Section: Introductionmentioning

confidence: 99%

Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma

Cui

Sun

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Cyclooxygenase-2 (COX-2) and interleukin-32 (IL-32) expression has been examined in various carcinomas and inflammations, and has been suggested to be significant in tumor progression and prognosis. The present study was conducted to investigate the expression of COX-2 and IL-32 in primary gastric B-cell lymphoma in order to define their clinical significance and their association with Helicobacter pylori (Hp) infection. COX-2 and IL-32 protein expression was detected in 31 primary gastric B-cell lymphoma patients and 19 chronic gastritis patients with immunohistochemistry. COX-2 and IL-32 expression was significantly higher in primary gastric lymphoma (PGL) tissues compared with gastritis tissues (51.6 vs. 21.1% for COX-2, P= 0.032; and 58.1 vs. 26.3% for IL-32, P= 0.029) and was significantly higher in Hp + lymphoma tissues compared with Hp -lymphoma tissues (66.7 vs. 20% for COX-2, P= 0.015; and 71.4 vs. 30% for IL-32, P= 0.029). In the PGL tissues, the expression level of COX-2 was positively correlated with the expression level of IL-32, and the two were each positively correlated with Hp infection (P= 0.004 for COX-2 and IL-32; P= 0.01 for COX-2 and Hp infection; and P= 0.003 for IL-32 and Hp infection). COX-2 expression was found to be significantly associated (P<0.05) with an aggressive tumor type, higher expression of Ki-67, frequent lymph node metastasis and advanced stage. IL-32 expression was found to be significantly correlated (P<0.05) with frequent lymph node metastasis and an advanced stage. The survival time was longer in the COX-2 -and IL-32 -lymphoma patients compared with the COX-2 + and IL-32 + lymphoma patients, but these differences were not statistically significant. These results suggested that Hp infection and the expression of COX-2 and IL-32 were closely linked with each other, and that the overexpression of COX-2 and IL-32 was correlated with tumor progression in primary gastric B-cell lymphoma, thus indicating potential novel therapeutic target.

show abstract

Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96)

Abstract: In this nonrandomized study (02/96), we reproduced the previous results of study 01/92 showing no disadvantage for an organ-preserving treatment. Therefore, primary stomach resection should be questioned.

Cited by 227 publications

References 26 publications

Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature

Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature

Lymphoproliferative Disorders of the Gastrointestinal Tract: A Review and Pragmatic Guide to Diagnosis

Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma

Contact Info

Product

Resources

About